NASDAQ:SPPI Spectrum Pharmaceuticals (SPPI) Stock Price, News & Analysis → 8,788% Return Predicted For THIS Crypto (already up 40% in 6 months) (From Paradigm Press) (Ad) Free SPPI Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.03▼$1.0350-Day Range$0.94▼$1.0352-Week Range$0.32▼$1.57VolumeN/AAverage Volume1.93 million shsMarket Capitalization$211.41 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Spectrum Pharmaceuticals alerts: Email Address Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r About Spectrum Pharmaceuticals Stock (NASDAQ:SPPI)Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.Read More Ad Porter & CompanyUrgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.Click here now to get what could be the most urgent, and most lucrative research, my team has ever r SPPI Stock News HeadlinesFebruary 21, 2024 | markets.businessinsider.comAssertio Holdings, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - ASRTFebruary 21, 2024 | markets.businessinsider.comLevi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming DeadlineMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.February 8, 2024 | markets.businessinsider.comLost Money on Assertio Holdings, Inc.(ASRT)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyFebruary 5, 2024 | markets.businessinsider.comAssertio Holdings, Inc. (NASDAQ: ASRT) INVESTOR ALERT: Berger Montague Advises Investors to Inquire About a Securities Fraud Class ActionFebruary 1, 2024 | stockhouse.comGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Assertio Holdings, Inc. (ASRT)February 1, 2024 | markets.businessinsider.comCLASS ACTION NOTICE: Berger Montague Encourages Assertio Holdings, Inc. (ASRT) Investors to Inquire About a Securities Fraud Class ActionJanuary 30, 2024 | stockhouse.comSHAREHOLDER ALERT: Levi & Korsinsky Notifies Assertio Holdings, Inc.(ASRT) Investors of a Class Action Lawsuit and Upcoming DeadlineMarch 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.January 26, 2024 | tmcnet.comINVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Assertio Holdings, Inc. (ASRT) InvestorsJanuary 13, 2024 | stockhouse.comINVESTOR ALERT: Levi & Korsinsky Notifies Shareholders of Assertio Holdings, Inc.(ASRT) of a Class Action Lawsuit and an Upcoming DeadlineJanuary 12, 2024 | finance.yahoo.comEye Melanoma Market Size Worth USD 9.56 Billion in 2032 | Emergen ResearchJanuary 10, 2024 | finance.yahoo.comVaccine Adjuvant Market Size Worth USD 1.75 Billion in 2032 | Emergen ResearchJanuary 9, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Assertio Holdings, Inc. (ASRT) InvestorsNovember 9, 2023 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Assertio Holdings, Inc. - ASRTJuly 24, 2023 | seekingalpha.comBuy Spectrum Pharmaceuticals For Exposure To Assertio HoldingsJuly 8, 2023 | fool.comSpectrum Pharmaceuticals (NASDAQ: SPPI)July 3, 2023 | benzinga.comMoore Kuehn Encourages SYNH, SPPI, ARNC and EMBK Investors to Contact Law FirmJune 30, 2023 | finance.yahoo.comSPPI - Spectrum Pharmaceuticals, Inc.May 26, 2023 | msn.comHC Wainwright & Co. Reiterates Spectrum Pharmaceuticals (SPPI) Neutral RecommendationMay 17, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 15, 2023 | msn.comJefferies Downgrades Spectrum Pharmaceuticals (SPPI)May 14, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ForecastsMay 10, 2023 | finance.yahoo.comQ1 2023 Assertio Holdings Inc Earnings CallMay 9, 2023 | msn.comSpectrum Pharmaceuticals rises as co. says its Q1 net sales up 54% Q/QMay 9, 2023 | finance.yahoo.comSpectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue EstimatesMay 5, 2023 | markets.businessinsider.comB.Riley Financial Remains a Hold on Spectrum Pharmaceuticals (SPPI)See More Headlines Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(617) 586-3900Fax702-260-7405Employees86Year Founded2002Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-263.04% Return on Equity-218.44% Return on Assets-66.16% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.38 Sales & Book Value Annual Sales$10.11 million Price / Sales20.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.15 per share Price / Book6.87Miscellaneous Outstanding Shares205,250,000Free Float199,704,000Market Cap$211.41 million OptionableOptionable Beta2.15 Social Links Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Thomas J. Riga (Age 48)Pres, CEO & Director Comp: $1.07MMs. Nora E. Brennan (Age 54)Exec. VP & CFO Comp: $46.25kMr. Keith M. McGahan J.D. (Age 47)L.L.M., Exec. VP, Chief Legal Officer & Corp. Sec. Comp: $948.26kMr. Michael A. GrabowExec. VP & Chief Bus. OfficerDr. Lyndah K. Dreiling M.B.A.M.D., Sr. VP of Clinical Devel.Key CompetitorsMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDARigel PharmaceuticalsNASDAQ:RIGLVerastemNASDAQ:VSTMXOMANASDAQ:XOMAView All CompetitorsInsidersNora BrennanSold 32,387 sharesTotal: $35,625.70 ($1.10/share) SPPI Stock Analysis - Frequently Asked Questions Should I buy or sell Spectrum Pharmaceuticals stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares. View SPPI analyst ratings or view top-rated stocks. How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.07. During the same quarter last year, the firm posted ($0.37) EPS. What ETF holds Spectrum Pharmaceuticals' stock? IQ Merger Arbitrage ETF holds 1,389,760 shares of SPPI stock, representing 0.29% of its portfolio. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). This page (NASDAQ:SPPI) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.